Corporate Newsletter April 2018_v5

NEWSLETTER2 Message from the CEO3 The Altascientist4 Bioanalytical Corner/Assay List5 Industry News6 Press Room7 Up Close and Personal9 Upcoming Events10 5 Things Private Equity Firms Look for When Investing

MESSAGE FROM OUR CEOAs an industry leader in early stage clinicalresearch, we are constantly evaluatingthe market to stay abreast of changes,and assess any impact they may haveon our business. The number of newand generic drugs being tested and/orsubmitted to the FDA are on the rise, andoutsourcing drug development is quicklybecoming a standard. As a result, ourbusiness is growing.As clients continue to entrust us with Chris Perkin,their drug development programs, we areconstantly evaluating our growth strategy. Chief Executive Officer,This year will be one of transformation for Altasciences Clinical ResearchAltasciences, but there are still lots ofkey questions that need to be answeredbefore we decide which course of actionwould fit best with our overall growth plan.In today’s unpredictable market, it’s hard to make any promises. But onething I can say for sure is no matter what new ventures we take on, we willcontinue to deliver the first-class service we have been providing clients forthe past two decades. We are extremely proud to be considered not only asa service provider, but a true partner they can rely on.I look forward to sharing exciting news with you in the very near future!

THE ALTASCIENTISTRevolutionizingtraditional medicinewith cannabis-basedmedicinal productsAltasciences has been conducting studies on cannabinoid-basedproducts for over 10 years and has run over 34 studies to date withcannabinoids or requiring cannabis users. We are at the forefront of testingvaping devices and combustibles, have extensive experience with productsdelivered by inhalation, and are experts in all the different delivery methodsof cannabinoid therapies. We designed andconducted a safety and tolerability studyon the world’s first cannabis extract(PPP001) being developed as a drug forregulatory submission by our sponsor TetraBio-Pharma, and will soon be initiating oursecond Phase I study for the sponsor, tocharacterize the safe use of cannabis oilmedicines in humans.Read the full case study in our most recentissue of The Altascientist. REQUEST YOUR COPY

BIOANALYTICAL CORNERFrom January to March 2018, we validated the following analytical methods.Click here to view the full Assay List. LATEST VALIDATED ANALYTICAL METHODSLC-MS/MS ASSAYS LBA ASSAYSPropafenone and Ciprofloxacin C-Reactive5-Hydroxypropafenone protein (CRP) Glucagon (dog plasma)Aminocaproic Acid PhloroglucinolNintedanib QuinidineCaffeine andparaxanthine Tranylcypromine (chiral assay)To meet the needs of both pharmaceutical and tobacco companies, ourvalidated methods include assays for cannabidiol (CBD) and nicotine inplasma, as well as a number of biomarkers of tobacco exposure. We haveaccess to a combined database of over 50,000 smokers and our leading20,000-square-foot laboratory has analyzed more than 10,000 study sampleswith a batch acceptance rate >97%, within a range of 0.2-100ng/mL, andapproximately 8,000 samples with a batch acceptance rate >94%, withina range of 0.2-50ng/mL. We have demonstrated long-term stability for up to483 days at -20 °C within those ranges.Ask our experts for more information on CONTACT USour bioanalytical capabilities regarding yoursmoking/vaping or cannabis-related studies.

INDUSTRY NEWSAdvancing public health and supporting the FDA’s vision of a world wheretobacco products would no longer create or sustain addiction is a priorityfor Altasciences. Our nicotine and Human Abuse Potential (HAP) studiesencourage manufacturers to explore product innovations that wouldmaximize potential benefits and minimize risk, allowing the FDA to regulatetobacco products based on the most current scientific knowledge.View our latest complimentary webinar.Assessing the Effects of New Tobacco/Nicotine Products on Human Health and Behaviour PRESENTERS: Dr. Graham Wood Dr. Michael Kong Chief R&D Officer Director, Medical Science LiaisonAltasciences Clinical Research Altasciences Clinical ResearchGET ON-DEMAND VIEWING

PRESS ROOMMarch 23, 2018Altasciences honored as the Best Early Phase CRO in North Americaby the 2018 Global Health and Pharma Biotechnological Awards READ MOREMarch 7, 2018Third iCardiac/ERT-Certified Site for Altasciences Clinical Research READ MOREMarch 1, 2018Altasciences nominated as the Most Successful Early PhaseResearch CRO (Preclinical & Phase I) by the Pharma IntelligenceClinical and Research Excellence Awards READ MOREJanuary 17, 2018Dr. Gaetano Morelli Joins Altasciences Clinical Research’sMedical Team READ MORE To get all our latest news, click here.

MEETMARIE-HÉLÈNE RAIGNEAUGeneral Manager, Altasciences, CanadaMarie-Hélène started her career as a BusinessDevelopment Manager at Future Electronics, laterjoining Charles River Laboratories as AccountManager in 2004. Following a successionof roles with increasing responsibilities,Marie-Hélène became Global Director ofMarketing and Business Development forCharles River Laboratories in 2011.Marie-Hélène joined Altasciences in 2012 asDirector of Business Operations and ClientServices for Montreal, and was promoted toSenior Director in 2013, and Executive Directorin 2014. She was appointed to her currentposition of General Manager of Altasciences’Canadian sites in 2015. She holds a Bachelor of Arts in Psychology from McGillUniversity and Executive MBA from the Université de Québec à Montréal.Throughout her career, Marie-Hélène’s focus has been to deliver exceptional qualityand customer service to an international client base of biotech and pharmaceuticalcompanies. Her level-headed, calm and reassuring personality, coupled with hercommunication skills and business sense, make her a trusted colleague and a go-toperson when the pressure is on.

With the legalization of marijuana under way, Marie-Hélène has been in ongoing discussions with governments and media to highlight the expertise Altasciences has with cannabinoid-based product research, and stressing the importance of conducting driving simulation studies to aid in establishing scientifically defendable regulations on driving after the consumption of cannabis. When not working, Marie-Hélène and her husband spend the majority of their time appreciating the joys of parenthood as they help their toddler discover new things, and manage the chaos that normally ensues.“ When speaking to clients about what makes their experience with Altasciences better than any other organization they have worked with, one element always referenced is the feeling that our people are genuinely invested in their projects, always willing to go the extra mile, and just really nice to work with. Altasciences recognizes that our people are our most important asset, because they allow us to stay on the cutting edge of innovation and are passionate about providing the best experience for our clients. Working alongside such enthusiastic individuals energizes me every day to step up to the challenge of making Altasciences an even better ”organization to work for and partner with. - Marie-Hélène Raigneau

UPCOMING EVENTSLet’s connect at upcoming industry events!Our management team and scientific experts will always make time to talk aboutyour upcoming drug development programs and ongoing projects.Be sure to catch the following poster presentations by our MethodDevelopment team at the 66th ASMS Meeting, June 3 to 7, in San Diego, CA. 1 Selective Quantitation of 1,3-Propanediol in Dog Plasma Using Differential Ion Mobility Spectrometry 2 A Selective Method for the Quantitation of Allopurinol in Human Plasma Using Differential Ion Mobility Spectrometry 3 Selective and Sensitive Quantitation of Fingolimod and Fingolimod Phosphate in Human Blood using Differential Ion-Mobility Spectrometry 4 Quantitation of Fenfluramine and Norfenfluramine in Mouse Cerebellum using a Novel SLE Prototype 5 Novel SLE Prototype vs Diatomaceous Earth: Evaluation of Phospholipid-Depletion, Matrix Effect and Recovery of Cortisol and 6β-Hydroxycortisol 6 Quantitation of the Monoclonal Antibody Rituximab Using Volumetric Absorptive Microsampling, Impact-Assisted Extraction, Trypsin Digestion and LC-MRM + Differential Mobility Spectrometry: A New Dimension in Selectivity and Sensitivity coupling SelexION+ Technology with the 6500+ presented at the SCIEX Users Meeting at the event!

5 THINGS PRIVATE EQUITY FIRMS LOOK FOR WHEN INVESTINGAs part of their continuous growth plans, many companieswill require capital infusion in order to grow their business,tap into new markets, or acquire new corporations.Receiving funding from private equity firms is one way toaccomplish this.Private equity firms are metrics driven. Every piece of the puzzle is dissectedin order to understand a company’s financials, market position and industrytrends. They tend to look for businesses that show clear growth potential insales and profits over the next three to five years, so they are able to sell thecompany to a corporate or financial buyer, or launch an IPO.

These are five key things private equity firms look for whenanalyzing an investment opportunity:Growth potential. Before private equity firms invest capital in a company,they assess the organization’s growth strategy to ensure that the businesscan grow, be it through the introduction of new products, by expandingits geographic reach, increasing its client base, building new partnershipsthrough mergers and acquisitions, or entering adjacent industries. If thetarget company is willing to take calculated risks to capitalize on industrytrends, that may pique their interest even more, as they are always lookingto maximize their returns.Cash flow. Private equity firms value a business based on their earningsbefore interest, taxes, depreciation, and amortization (EBITDA). Cash flowis analyzed closely to ensure that the business has a stable and recurringcash flow and is not too sensitive to economic downturns, which helps yielda profit for the investor when they decide to sell the business. Private equityfirms tend to request weekly, monthly, and quarterly cash flow models tomonitor and ensure the risk factors associated to liquidity are minimized.Return on investment. Private equity firms are looking to invest ina business that will yield the most profits in the short- to mid-term. Theyare attracted to companies that have demonstrated an ability to achieveattractive returns on capital expenditures and other forms of investment.A strong management team. Although most private equity firms willprovide strategic guidance, they tend to rely on the existing managementteam to make the transition seamless and execute the day-to-day operations.Having a skilled and experienced management team is invaluable to privateequity firms as they need to have absolute confidence in their ability to makedecisions autonomously.

A contingency plan. In other words, an exit strategy. When evaluating an investment opportunity, private equity firms must also consider downside protection. Like all business ventures, investments have their ups and downs; if the investment does not meet its growth plan, having an exit strategy in place and knowing how to generate an adequate return is an important factor that influences their decision-making process when considering whether or not to invest in a business. When planning your company’s growth plan, if you require capital investment to fulfill your objectives and expand your business, ensure that all these factors are well thought out. Be prepared to proactively address these critical questions that potential investors will be considering when reviewing the overall growth potential of their investment in your company.Article References:http://www.benchcapital.ca/what-private-equity-investors-want-to-see-in-your-businesshttp://fortune.com/2012/07/09/5-questions-every-private-equity-investor-needs-to-askhttps://www.harriswilliams.com/sites/default/files/industry_reports/2014.4.17_contract_research_organizations.pdfhttps://www.linkedin.com/pulse/8-things-private-equity-firms-look-company-daniel-gillethttp://www.onetoonecf.com/en/enrique-quemada-8-things-private-equity-firms-look-for-in-companieshttp://www.streetofwalls.com/finance-training-courses/private-equity-training/private-equity-investment-criteria

[email protected] Armand-Frappier Blvd. 10103 Metcalf Ave. 4837 Amber Valley ParkwayLaval, QC H7V 4B3 Overland Park, KS 66212 Fargo, ND 58104Canada United States United States450 973-6077 913 696-1601 701 551-3737algopharm.com vinceandassociates.com algopharm.com © 2018 Altasciences. All Rights Reserved.